Status:
UNKNOWN
The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori
Lead Sponsor:
Huazhong University of Science and Technology
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The eradication rate of standard quadruple therapy has become less successful due to low compliance and high resistance to antibiotics. Therefore, it is necessary to develop new treatment strategies t...
Detailed Description
In China, the first-line therapy to treat Helicobacter pylori (Hp) consists of a bismuth-based proton pump inhibitor (PPI) and two antibiotics for 14 days.But, eradication has become less successful d...
Eligibility Criteria
Inclusion
- Helicobacter pylori infected patients comfirmed by 13C/14C UBT
- age 18\~65
Exclusion
- prior Hp eradication therapy including amoxicillin and clarithromycin
- previous gastric resection
- allergic to the drugs used in this study
- previous use of proton pump inhibitors, bismuth, H2 receptor antagonist or antibiotics, probiotics within 4 weeks of the study
- Patients who were pregnant or lactating
- Patients taking NSAIDs, alcoholic or with other serious disease (e.g. hepatopathy, heart disease, nephropathy#diabete mellitus, hypertension…) effect the evaluation of this study
- Can't express the complaint correctly
Key Trial Info
Start Date :
March 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
672 Patients enrolled
Trial Details
Trial ID
NCT05189444
Start Date
March 25 2022
End Date
December 31 2022
Last Update
March 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji Hospital, Tongji Medical College, HUST
Wuhan, Hubei, China, 430030